Malaria vaccines: New hope in old ideas

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 167-172

  Pinzon Charry, Alberto ^a   Anderson, Vivian ^a   McPhun, Virginia ^a   Wykes, Michelle ^a   Good, Michael F ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; ERYTHROCYTE BAND 1 PROTEIN; ERYTHROCYTE BAND 3 PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ERYTHROCYTE; GENE TARGETING; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM; REVIEW; RISK ASSESSMENT;

EID: 33746825884     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.06.002     Document Type: Review

References (41)

1. World Health Organization. WHO Expert Committee on Malaria. World Health Organ. Tech. Rep. Ser. 892 (2000) 1-74
2. Snow R.W., et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-217
3. Graves P.M. Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria. Ann. Trop. Med. Parasitol. 92 (1998) 399-410
4. Webster D., and Hill A.V. Progress with new malaria vaccines. Bull. World Health Organ. 81 (2003) 902-909
5. Kemp D.J., et al. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc. Natl. Acad. Sci. U S A 80 (1983) 3787-3791
6. Ellis J., et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302 (1983) 536-538
7. Ballou W.R., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1 (1987) 1277-1281
8. Herrington D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 (1987) 257-259
9. Ballou W.R., et al. Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. 71 (2004) 239-247
10. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
11. Alonso P.L., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
12. Daubersies P., et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. 6 (2000) 1258-1263
13. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
14. Webster D.P., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U S A 102 (2005) 4836-4841
15. Moorthy V.S., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1 (2004) e33
16. Hirunpetcharat C., et al. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. J. Immunol. 162 (1999) 7309-7314
17. Kumar S., et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 68 (2000) 2215-2223
18. Lawrence, G.W. et al. (1997) Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15, 176-178
19. Saul A., et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 (1999) 3145-3159
20. Deans J.A., et al. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 10 (1988) 535-552
21. Anders R.F., et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 (1998) 240-247
22. Collins W.E., et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51 (1994) 711-719
23. Ferreira M.U., et al. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 304 (2003) 65-75
24. Escalante A.A., et al. Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol. Biochem. Parasitol. 113 (2001) 279-287
25. Chen Q., et al. Identification of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) as the rosetting ligand of the malaria parasite P. falciparum. J. Exp. Med. 187 (1998) 15-23
26. Baruch D.I., et al. Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc. Natl. Acad. Sci. U S A 99 (2002) 3860-3865
27. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185 (2002) 820-827
28. Carter R. Transmission blocking malaria vaccines. Vaccine 19 (2001) 2309-2314
29. National Institute of Allergy and Infectious Diseases, NIH Bethesda. (2002) The_Jordan_Report 20th Anniversary Accelerated Development of Vaccines
30. Hoffman S.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185 (2002) 1155-1164
31. Pombo D.J., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360 (2002) 610-617
32. Clyde D.F., et al. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266 (1973) 169-177
33. Hoffman S.L., et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 237 (1987) 639-642
34. Scheller L.F., and Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. U S A 92 (1995) 4066-4068
35. Mueller A.K., et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167
36. Mueller A.K., et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. U S A 102 (2005) 3022-3027
37. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206 (2003) 3803-3808
38. Good M.F. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 21 (2005) 29-34
39. Elliott S.R., et al. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. 73 (2005) 2478-2485
40. Schellenberg D., et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365 (2005) 1481-1483
41. Su Z., et al. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect. Immun. 71 (2003) 5178-5187